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ABSTRACT
Here we report that the PI3K/Akt1/IL-6/STAT3 signalling pathway regulates 
generation and stem cell-like properties of Non-Small Cell Lung Cancer (NSCLC) tumor 
initiating cells (TICs). Mutant Akt1, mutant PIK3CA or PTEN loss enhances formation 
of lung cancer spheroids (LCS), self-renewal, expression of stemness markers and 
tumorigenic potential of human immortalized bronchial cells (BEAS-2B) whereas Akt 
inhibition suppresses these activities in established (NCI-H460) and primary NSCLC cells. 
Matched microarray analysis of Akt1-interfered cells and LCSs identified IL-6 as a critical 
target of Akt signalling in NSCLC TICs. Accordingly, suppression of Akt in NSCLC cells 
decreases IL-6 levels, phosphorylation of IkK and IkB, NF-kB transcriptional activity, 
phosphorylation and transcriptional activity of STAT3 whereas active Akt1 up-regulates 
them. Exposure of LCSs isolated from NSCLC cells to blocking anti-IL-6 mAbs, shRNA 
to IL-6 receptor or to STAT3 markedly reduces the capability to generate LCSs, to 
self-renew and to form tumors, whereas administration of IL-6 to Akt-interfered cells 
restores the capability to generate LCSs. Finally, immunohistochemical studies in 
NSCLC patients demonstrated a positive correlative trend between activated Akt, IL-6 
expression and STAT3 phosphorylation (n = 94; p < 0.05). In conclusion, our data 
indicate that aberrant Akt signalling contributes to maintaining stemness in lung cancer 
TICs through a NF-kB/IL-6/ STAT3 pathway and provide novel potential therapeutic 
targets for eliminating these malignant cells in NSCLC.
INTRODUCTION
Lung cancer is the leading causes of cancer-related 
mortality worldwide, with a 5-year survival rate of 
only 15% for NSCLC [1]. One of the main causes of 
disease relapse is the emergence of cancer cells resistant 
to therapy. This phenomenon has been attributed to 
a population of cells endowed with tumour-initiating 
potential that support the growth of NSCLC [2–4]. 
These cells, known as Tumour initiating cells (TICs), 
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have a high capacity for self-renewal and multi-lineage 
differentiation and are believed to be responsible for 
tumor development, recurrence and dissemination as 
well as the acquisition of drug resistance [3]. In the 
experimental setting, TICs are able to grow as spheres 
under non-adherent, serum-free conditions and show 
high clonogenic growth in vitro and tumorigenic potential 
in vivo. TICs isolated from NSCLCs are characterised 
by the expression of specific markers including CD133, 
Oct-4 and ABCG2 [5–9]. However, the influence of 
specific oncogenic pathways on the growth and survival 
of TICs in NSCLC remains relatively unknown. Among 
the multiple pathways that are activated in NSCLC TICs, 
recent evidence indicated that the phosphatidylinositol 
3-kinase (PI3K)/Akt pathway may play a role in survival 
and proliferation of cancer stem-like cells [10–12]. 
Moreover, the sustained activation of the EGFR/SRC/
Akt signaling has been implicated in the regulation of 
self-renewal, growth and expansion of the side population 
compartment of NSCLC cells [13].
The serine/threonine protein kinases Akt represent the 
main known end-point of PI3K signaling. Akt is activated 
by recruitment to the cell membrane via binding of its 
PH domain to 3′-phosphorylated phosphatidyl-inositols 
generated by PI3K and subsequent phosphorylation at 
T308 and S473 [14, 15]. Conversely, the lipid phosphatase 
PTEN attenuates Akt activation by dephosphorylating the 
3′ position of phosphatidyl-inositols [16].
Expectedly, among the different molecular lesions 
that contribute to the development of NSCLC aberrant 
Akt activation is a frequent event [17, 18]. Akt kinases 
can be activated through several mechanisms, which 
result from distinct and often mutually exclusive events 
that include activating mutations or amplification of 
Akt1, Akt2 and Akt3, mutations of upstream activators 
(KRAS, PIK3CA), or loss of upstream inhibitors 
(PTEN) [17, 19]. We have recently identified a somatic 
mutation in the gene encoding Akt1 resulting in a 
glutamic acid to lysine substitution at amino acid 17 
(E17K) in a subset of NSCLC patients with increased 
Akt activity [20]. The mutant K17 residue increases 
the affinity for PI(4,5)P2, enhancing plasma membrane 
recruitment and activity [21, 22]. Accordingly, 
endogenous Akt1-E17K mutant detected in lung 
cancer cells shows enhanced membrane localization 
and activity [20, 21]. Nevertheless, the molecular 
mechanisms whereby Akt1-E17K promotes cancer in 
the human remain to be fully understood. Recently we 
have shown that Akt1-E17K mutant is able to transform 
lung epithelial cells [23]. In this manuscript, we provide 
complementary biochemical and biological evidence that 
aberrant signalling through the PI3K/Akt pathway, due 
to gain-of-function mutation in Akt1 (E17K) or PIK3CA 
(E545K) or to PTEN loss, regulates self-renewal of 
NSCLC TICs in vitro and tumor growth in vivo by 
activating the NF-kB/IL-6/STAT3 axis.
RESULTS
Activation of PI3K/Akt pathway confers 
increased spheroid-forming ability and highly 
tumorigenic potential to bronchial epithelial cells
Aberrant Akt activation is a frequent event in 
NSCLC that results from gain-of-function mutations of 
PIK3CA, loss of PTEN or activating mutations of Akt1 
itself [17–19]. Here we have investigated whether and how 
the activated PI3K/Akt pathway influences the generation 
and/or stem cell-like properties of TICs. As model system 
we used human bronchial epithelial cells (BEAS-2B), 
a non-tumorigenic line that had been immortalised by 
infection with Adenovirus 12/SV40 hybrid virus (BEAS-
2B) [35–38]. After lentiviral-transduction control BEAS-
2B (BEAS-C), BEAS-Akt1-E17K, BEAS-PIK3CA-
E545K and BEAS-shPTEN cells were isolated and 
expanded [23]. The presence of the exogenous mutant 
Akt1, mutant PIK3CA or endogenous PTEN proteins 
was detected by immunoblot ([23] and Supplemental 
Figure S1A, respectively). The status of the PI3K/Akt 
pathway was determined by analysis of AKT and/or GSK3 
phosphorylation ([23] and Supplemental Figure S1A, 
respectively). Similarly to what described previously for 
mutant Akt1-E17K [23], active PIK3CA (E545K) or PTEN 
loss render human bronchial epithelial cells BEAS-2B 
tumorigenic (Figure S1B). This high tumorigenic potential 
suggested that activation of the PI3K/Akt pathway may 
affect number and properties of NSCLC TICs.
To investigate the role of aberrant PI3K/Akt 
signalling in NSCLC TICs, BEAS-C, BEAS-Akt1-E17K, 
BEAS-PIK3CA-E545K and BEAS-shPTEN cells were 
cultured in low adhesion conditions in sphere medium. 
Mutant Akt1 in BEAS-2B cells produced a pronounced 
increase in the number of LCSs (Figure 1A), with 
virtually all LCSs larger than 100 μm (Figure 1B). In 
addition, while BEAS-C gave rise to constant LCS 
number throughout the generations in serial propagation 
assays (~20 out of 103 plated cells, 2% on average), 
the expression of mutant Akt1-E17K induced a marked 
increase in the number of LCS-forming cells over 
passages from 20/103 plated cells at passage 1 to 
120/103 plated cells at passage 9 (Figure 1C), which 
was paralleled by an increase in the expression of mRNA 
encoding stemness-related markers such as Oct-4, Nanog 
and Sox2 (Figure 1D). Finally, we found that BEAS-
Akt1-E17K LCSs were able to efficiently sustain tumor 
growth in vivo. Serial dilutions of BEAS-C and BEAS-
Akt1-E17K cells grown as LCSs (4 × 103, 4 × 104) were 
injected subcutaneously into NOD/SCID mice and 
monitored for tumor appearance up to ~7 months. Mice 
injected with BEAS-C LCSs (4 × 103, 4 × 104) yielded 
no tumor (n = 8 mice/group) whereas LCSs derived from 
BEAS-Akt1-E17K cells (4 × 103, 4 × 104) promoted 
formation of poorly differentiated carcinomas positive 
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Figure 1: Mutant Akt1-E17K increases formation of LCSs. A. Number of primary LCSs generated from control BEAS-2B cells 
or from the corresponding cells infected with pLenty-Akt1-E17K. **p < 0.01. B. Analysis of size distribution (μm) of LCSs generated 
from control BEAS-C and BEAS-Akt1-E17K cells by phase-contrast microscopy ***p < 0.001. C. Number of LCSs generated from 
control BEAS-C and BEAS-Akt1-E17K cells during serial passages expressed as mean ± SD. D. Relative mRNA expression of stemness 
genes by Q-RT-PCR in BEAS-C and BEAS-Akt1-E17K cells. E. Tumor growth of primary LCS generated from BEAS-Akt1-E17K cells 
(4 × 103, 4 × 104), injected into the flank of NOD/SCID mice (n = 8/group); data are shown as mean ± SD. F. Representative images of 
CK7 and CK34 immunostaining of tumours generated from single cell suspensions of primary LCSs derived from BEAS-Akt1-E17K cells 
subcutaneously injected into the flank of NOD/SCID and explanted 15–20 weeks after injection. Magnification as indicated.
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for cytokeratins (CK7, CK34) in 7/8 and 8/8 mice, 
respectively (Figure 1E, 1F). No tumor was detected in 
mice injected with the same numbers (4 × 103, 4 × 104) 
of BEAS-C or BEAS-Akt1-E17K grown in adherent 
conditions.
Results for mutant PIK3CA or PTEN loss are 
reported in Figure S2. Similarly to BEAS-Akt1-E17K 
cells, BEAS cells expressing mutant PIK3CA or silenced 
for PTEN showed a pronounced increase in the number 
and size of LCSs generated, expressed consistently higher 
mRNA levels of Oct-4, Nanog and Sox2, and were able 
to efficiently sustain tumor growth in vivo as LCSs at low 
number (Supplemental Figure S2A–S2E).
Altogether, these results indicate that aberrant 
signalling through the PI3K pathway – induced by mutant 
Akt1, PIK3CA or by PTEN loss - significantly increases 
the percentage of cells able to initiate in vitro growth as 
spheroids enriched in TICs that efficiently support tumor 
growth in vivo.
Inhibition of Akt signalling impairs formation 
and maintenance of LCSs
As a complementary approach to assess the 
importance of Akt1 signalling in NSCLC TICs we 
suppressed Akt1 expression in an established lung cancer 
cell line (NCI-H460) that harbours an activating mutation 
of PIK3CA (E545K) and in one primary short-term culture 
(PEd/10) derived from pleural effusions of lung cancer 
patients that engraft very efficiently (10–16 weeks latency) 
giving rise to adenocarcinoma [24].
NCI-H460 and PEd/10 cells were transduced with 
lentivirus expressing three different shRNAs (clones 
#1, #2 and #3) to Akt1. Silencing of Akt1 in NCI-H460 
and PEd/10, as assessed by immunoblot (Supplemental 
Figure S3A), resulted in reduced expansion of tumors 
generated by NSCLC cells injected into immunodeficient 
mice (n = 5/group) (Supplemental Figure S3B and S3C, 
respectively), indicating that Akt1 plays a significant role 
in the malignant behaviour of NSCLC cells. Suppression 
of Akt1 in NCI-H460 cells produced a pronounced 
decrease in the number and size of LCSs compared to 
control cells (Figure 2A). Most LCSs (~50%) generated 
by parental NCI-H460 or NCI-H460-scr, were larger 
than 100 μm, differently from those generated by NCI-
H460-shAkt1 (Figure 2B). Similar results were obtained 
in primary NSCLC cells PEd/10 (Figure 2C and 2D). In 
addition, whereas the number of PEd/10-scr LCS-forming 
cells increased steadily throughout the generations in 
self-renewal assays (from approximately 2% to more 
than 10%), the suppression of Akt1 expression prevented 
the increase in the number of LCS-forming cells over 
10 passages (Figure 2E). Accordingly, Akt1 knock-down 
also reduced mRNA expression of stem cell markers in 
NCI-H460 and PEd/10 cells (Figure 2F left and right, 
respectively).
Since the knock-down of Akt1 did not completely 
abrogate the capability to form LCSs, we reasoned 
that in NSCLC cells Akt1 function could be partially 
complemented by other Akt isoforms. Of these, Akt2 
expression is ubiquitous whereas Akt3 shows a more 
restricted expression pattern [39]. Therefore, we decided 
to interfer NCI-H460 and PEd/10 cells with lentivirus 
expressing shRNA to Akt2, to determine the relative 
effects of Akt1 and/or Akt2 signalling in NSCLC 
TICs. Similarly to Akt1 suppression, also the silencing 
of Akt2 in NCI-H460 and PEd/10 cells produced a 
decrease in the number and size of LCSs (Supplemental 
Figure S4A–S4F). However, we were not able to obtain 
complete  suppression of both isoforms, thus the double 
interfered cells could not be used to determine the effects 
of complete suppression of Akt signalling in NSCLC 
TICs (not shown). Therefore, we used a pharmacological 
inhibitor of all Akt isoforms (MK2206) and an inhibitor 
of the most important upstream activator of Akt 
(LY294002) to determine the effects of Akt signalling in 
NSCLC TICs. We found that exposure of NSCLC cells to 
MK2206 or LY294002 suppressed and/or decreased Akt 
phosphorylation (Figure 3A) and significantly impaired in 
a dose-dependent manner spheroid-forming capability of 
NSCLC cells (Figure 3B, left and right respectively). It is 
of note that the established cell line NCI-H460 was less 
sensitive than the primary PEd/10 cells to both inhibitors, 
and in particular to LY294002, possibly because these 
cells carry a constitutively activated allele of PIK3CA.
These results suggested that the modulation of Akt 
activity is able to regulate the percentage of NSCLC cells 
able to initiate growth as spheroids, which are apparently 
enriched in putative TICs.
IL-6 is a critical target of Akt signalling in 
NSCLC TICs
We proceeded to identify the downstream targets of 
constitutive Akt1 signalling that regulate generation and/
or maintenance of LCSs. To this aim, we first identified 
genes that are regulated by Akt1 by comparing the 
transcriptome of NCI-H460 cells with that of NCI-H460-
shAkt1. We identified 336 differentially regulated transcripts 
(DEGs) (fold change cut-off: 1.5; p < 0.05), of which 161 
were up-regulated and 175 were down-regulated (“Akt1 
signature”, listed in Supplemental Table S1). Then we 
identified genes that are implicated in the generation and/
or maintenance of LCSs by comparing the transcriptome 
of NCI-H460 cells grown as LCSs with that of NCI-H460 
cells grown in adherent condition. As listed in Supplemental 
Table S2 (“LCS signature”) we identified 1715 DEGs 
(fold change cut-off: 1.5; p < 0.05), of which 909 were 
up-regulated and 806 were down-regulated. To determine 
what subset of Akt-regulated genes was implicated in 
the generation and/or maintenance of NSCLC LCSs, we 
matched the “Akt1 signature” with the “LCS signature”. 
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Figure 2: Akt1 regulates formation and maintenance of NSCLC LCS. A. Number of primary LCSs generated from NCI-H460 
cells or the corresponding cells infected with lentivirus expressing shRNAs to Akt1 (clones #1, #2, #3, respectively). Data are shown as 
mean ± SD. ***p < 0.001. B. Analysis of size distribution (μm) of LCSs generated from NCI-H460 or NCI-H460-shAkt1 cells by phase-
contrast microscopy *p < 0.05. C. Number of primary LCSs generated from PEd/10 cells or the corresponding cells interfered for Akt1 
(clones #1, #2, #3, respectively) *p < 0.05. D. Analysis of size distribution (μm) of LCSs generated from PEd/10 cells by phase-contrast 
microscopy ***p < 0.001. E. Representative analysis of primary LCSs generated from PEd/10 cells or the corresponding cells interfered 
for Akt1 during serial passages (n = 10). F. Left, relative mRNA expression of stemness genes by Q-RT-PCR in NCI-H460 cells and 
derivatives; right, relative mRNA expression of stemness genes by Q-RT-PCR in PEd/10-scr cells and derivatives.
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As shown in the Venn diagram of Supplemental 
Figure S5A, we identified 152 DEGs that are common 
between Akt1-interfered and LCS-derived NCI-H460 cells 
(see Supplemental Table S3). Analysis of DEGs indicated 
that several genes (i.e. cytokines IL-2, IL-6, IL-8, IL-1) 
known to be involved in migration, metastasis and stem cell 
maintenance, are apparently co-regulated in Akt1-interfered 
NCI-H460 and in LCSs (see Supplemental Tables S1–S3 and 
Heat Map in Supplemental Figure S5B). For the rest of the 
manuscript we have focused our attention on IL-6 because 
this gene presented the most consistent modulation in the 
matching of “Akt1 signature” and “LCS signature” as shown 
in Supplemental Figure S5B. The array data are loaded into 
ArrayExpress with accession number E-MTAB-1699.
We confirmed that IL-6 expression is down-regulated 
in NSCLC cells interfered for Akt1 by quantitative 
RT-PCR (Figure 4A, left and right panels) but is 
up-regulated in BEAS-2B cells expressing Akt1-E17K, 
PIK3CA-E545K or shPTEN (Figure 4B and Supplemental 
Figure S5C, respectively). NCI-H460 cells and PEd/10 
cells interferred for Akt1 showed a marked reduction of 
IL-6 secretion (Figure 4C). Notably, IL-6 is expressed at 
higher levels in LCSs than in adherent cells (Figure 4D). 
The finding that IL-6 receptor (IL-6r) and gp130 mRNAs 
were detected in all cellular systems under study (28 and 26 
number of cycles respectively, Supplemental Figure S5D) 
indicated that human lung cells may be responsive to 
secreted IL-6. Taken together these results indicate that 
Akt1 regulates the IL-6/IL-6r signalling axis, and that this 
pathway is significantly up-regulated in LCSs.
IL-6 expression is stimulated by NF-kB, whose 
activity is regulated by Akt through phosphorylation 
of IkB kinases (IkKs). Accordingly, we found that 
interference with Akt1 decreased phosphorylation of 
IkKα/β (S176 /180) and of IkB (S32), thus resulting in a 
2-fold stabilization of IkB (Figure 5A, lane -). The effect 
of suppressing Akt1 in PEd/10 cells was more evident after 
treatment of PEd/10-scr and PEd/10-shAkt1 cells with 
increasing doses of TNF-α (0.1, 1 ng/ml) (Figure 5A). 
Conversely, expression of Akt1-E17K in BEAS-2B 
cells increased phosphorylation of both IkKα/β and IkB, 
resulting in the destabilization of IkB (Figure 5B). The 
resulting stabilization of IkB in NCI-H460-shAkt1 and 
PEd/10-shAkt1 was associated with decreased NF-kB 
Figure 3: Akt signalling is required for maintenance of NSCLC LCSs. A. Immunoblot analysis of Akt phosphorylation status in 
NCI-H460 and PEd/10 cells treated with MK-2206 and LY294002 at the indicated concentrations. B. Analysis of primary LCSs generated 
from NCI-H460 and PEd/10 cells treated with MK 2206 and LY294002 at the indicated concentrations. ***p < 0.001, **p < 0.01, *p < 0.05.
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transcriptional activity as evaluated by the measure of 
NF-kB activity in reporter assays (Figure 5C, left and 
right panels, respectively). Finally, in agreement with the 
hypothesis that NF-kB activity is required for spheroid 
generation, we found that an IkK inhibitor (BAY11-
7082), which induces IkB stabilization, strongly reduced 
formation of LCSs (Figure 5D–5E). It is worth noting 
that, as in the case of Akt or PI3K inhibitors, NCI-H460 
cells were less sensitive to BAY11-7082 than the primary 
PEd/10 cells.
IL-6/IL-6 receptor axis is necessary for NSCLC 
cells to form LCSs and tumors
Subsequently, we investigated the functional role 
of IL-6 in the generation and maintenance of NSCLC 
Figure 4: Akt1 regulates IL-6 expression in NSCLC cells. A. Relative mRNA expression of IL-6 by Q-RT-PCR in NCI-H460 
cells, PEd/10, and derivatives. *p < 0.05, ***p < 0.001. B. Relative mRNA expression of IL-6 by Q-RT-PCR in BEAS-2B and derivatives 
****p < 0.0001. C. Levels of secreted IL-6 by ELISA in NCI-H460 cells and derivatives (1,500 and 635 pg/ml, respectively), in PEd/10 
cells and derivatives (100 pg/ml and 5 pg/ml, respectively) *p < 0.05, **p < 0.01. D. Q-RT-PCR analysis of mRNA expression of IL-6 in 
adherent and LCSs generated from NCI-H460 and PEd/10.
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LCSs, by exposing secondary NCI-H460 and PEd/10 
LCSs to a blocking mAb to IL-6 (anti-IL-6). We 
found that anti-IL-6 markedly reduced the capability 
of NCI-H460 and PEd/10 cells to generate secondary 
spheres (Figure 6A, left and right panels, respectively). 
Conversely, we observed that administration of IL-6 to 
Akt1-interfered NCI-H460 and PEd/10 cells, restored 
the capability to generate LCSs (Figure 6B, left and right 
panels, respectively). Similarly, we found that treatment 
of BEAS-Akt1-E17K cells with anti-IL-6 reduced their 
spherogenic capability whereas treatment of BEAS-C 
cells with IL-6 increased the number of secondary LCSs 
(Figure 6C).
In agreement with these results the knock-down 
of IL-6r through use of two different shRNAs (clones 
#1 and #2) (Supplemental Figure S6A) induced a 
pronounced decrease in the number (Figure 6D) and 
size (Figure 6E) of LCSs generated by PEd/10 cells. 
In addition, whereas in PEd/10-scr cells the number of 
LCS-forming cells increased steadily throughout the 
Figure 5: Akt1 regulates NF-kB activity in NSCLC cells. A. Immunoblot analysis of members of the NF-kB pathway in PEd/10 
and derivative cells treated with increasing doses of TNF-α (0.1, 1 ng/ml). B. Immunoblot analysis of members of the NF-kB pathway in 
BEAS-C and BEAS-Akt1-E17K cells. C. Luciferase assay of NF-kB activity in NCI-H460, PEd/10 cells and derivatives interfered for Akt1 
transfected with a reporter containing a NF-kB-responsive promoter, *p < 0.05. D. Immunoblot analysis of IkBα in NCI-H460 and PEd/10 
cells treated with BAY11-7082. E. Analysis of spheroid forming capability of NCI-H460 and PEd/10 cells treated with BAY11-7082, 
*p < 0.05, ***p < 0.001.
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generations in self-renewal assays, the suppression of 
IL-6r strongly prevented the increase in the number 
of LCS-forming cells, abolishing it completely after 
5 passages (Figure 6F).
Altogether, these results indicated that the IL-6/
IL-6r axis plays a significant role downstream Akt1 
signalling in human bronchial epithelial cells and that it 
contributes to the malignant behaviour of NSCLC cells.
Figure 6: IL-6 sustains formation of NSCLC LCSs. A. Effects of anti-IL-6 mAb (3.0 μg/ml) on the formation of secondary LCSs in 
NCI-H460 and PEd/10 cells. ***p < 0.001; **p < 0.01. B. Effects of IL-6 administration (20 ng/ml) on the formation of secondary LCSs in 
NCI-H460 and derivatives, PEd/10 and derivatives. **p < 0.01. C. Effects of anti-IL-6-mAb (3.0 μg/ml) or IL-6 administration (20 ng/ml) 
on the formation of LCSs generated from BEAS-C and BEAS-Akt1-E17K. *p < 0.05. D. Number of LCSs generated from PEd/10 cells or 
the corresponding cells interfered for IL-6r (PEd/10-shIL-6r; clones #1, #2). ***p < 0.001. E. Analysis by phase-contrast microscopy of size 
distribution (μm) of LCSs generated from PEd/10-scr and PEd/10-shIL-6r cells, ***p < 0.001. F. Number of LCSs formed from PEd/10-scr 
and PEd/10-shIL-6r cells during serial passages (n = 5).
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STAT3 regulates efficiency of LCS formation 
and tumorigenicity of NSCLC cells
The latent transcription factor Signal Transducer 
and Activator of Transcription 3 (STAT3) is a pivotal 
downstream mediator of IL-6 signalling that plays a role in 
stem cells and tumorigenicity [40, 41]. Thus, we examined 
the status of STAT3 activation in NSCLC cells interfered for 
Akt1 or IL-6r. Suppression of Akt1 and/or IL-6r in NSCLC 
cells strongly decreased the levels of phosphorylated 
STAT3 (Y705) (Figure 7A). On the other hand, in keeping 
with a role for STAT3 in TICs, phosphorylated STAT3 
was greater in LCSs than in the corresponding adherent 
cells (Figure 7B). Silencing of STAT3 with two different 
shRNAs (Supplemental Figure S6B, clones #1 and #2, 
respectively) or pharmacological inhibitors (Sta-21 and 
Stat3 Inhibitor XIII) produced a significant decrease in 
the number and in the size of LCSs generated by NSCLC 
cells (Figure 7C–7E) and impaired tumor growth in mice 
(n = 5/group) (Figure 7F).
Finally, we performed chromatin immunoprecipitation 
(ChIP) assay to investigate STAT3 activity in PEd/10-scr 
and the corresponding cells interfered for Akt1. Chromatin 
was immunoprecipitated with anti-STAT3 or rabbit IgG 
antibodies from PEd/10-scr and PEd/10-shAkt1 cells 
grown in starvation medium or complete medium in the 
presence or absence of IL-6 and DNA from the JunB 
promoter was amplified by PCR. We found that STAT3 
promoter occupancy was reduced of 40% in PEd/10-
shAkt1 and of 32% in PEd/10-shSTAT3 cells compared 
with PEd/10-scr cells in complete medium (Figure 7G). 
Accordingly, mRNA expression of three known STAT3 
targets (Cyclin D2, JunB and SerpineA1) [42, 43] was 
significantly reduced in NSCLC cells interfered for Akt1 
(Figure 7H).
Altogether, these results indicate that STAT3 plays 
a significant role downstream Akt1 signalling in human 
malignant NSCLC cells.
Akt activation correlates with IL-6 and STAT3 
activity in primary NSCLC
Finally, we went back to human tissues and analysed 
the activation status of the Akt1/IL-6/STAT3 pathway in 
human NSCLC (n = 104), arrayed onto TMAs (TMA-
LC1, TMA-LC2) as described [19]. Read-out were: the 
phosphorylation status of S473 for activated Akt (pAkt), 
the phosphorylation status of Y705 for activated STAT3 
(pSTAT3), immunostaining with anti-IL-6 antibodies 
for IL-6 levels. Of 104 cases arrayed on the TMAs 
(49 ADC, 34 SCC, 21 different histotypes), 96 could 
be properly analysed for pAkt, 102 for IL-6 and 99 for 
pSTAT3. Simultaneous staining for all proteins was 
available in 94 samples. As control, 23 matched normal 
samples were used. Evaluation criteria are reported 
in Materials and Methods. Results are summarized in 
Supplemental Table S4. Representative stainings are 
shown in Figure 8A. As expected from previous work 
from our lab and literature, we did not find activation of 
Akt and STAT3 and IL-6 expression in most of the 23 
control tissues (not shown). Akt activation was observed 
in 32 out of 96 NSCLC (13/45 ADC, 11/32 SCC, 8/19 
tumors with other histotypes, respectively) as already 
reported [19]; IL-6 expression was observed in 38 out of 
102 NSCLC analysed (18/49 ADC, in 13/34 SCC and in 
7/19 tumors with other histotypes); STAT3 activation was 
observed in 36 out of 99 NSCLC analysed (19/46 ADC, 
10/33 SCC, 7/20 tumors with other histotypes).
Tables 1 and 2 summarize the results of single 
and multiple correlations among Akt activation, IL-6 
expression and STAT3 activation. We found a significant 
trend that correlated activated Akt (pAkt) and the 
combined status of IL-6 positive/pSTAT3 positive (n = 94; 
p = 0.044) and between the combined status of pAkt/IL-6 
positive and pSTAT3 (n = 94; p = 0.029). In fact, 34/44 
(79%) NSCLC patients that were IL-6 negative/pSTAT3 
negative were also negative for pAkt whereas 7/16 (41%) 
NSCLC patients that were IL-6 positive/pSTAT3 positive 
were also positive for pAkt. These data suggest that 
activation of the PI3K/Akt pathway is apparently required 
for the synthesis of IL-6 and the activation of STAT3, 
though not sufficient in all cases.
On the other hand, of the 43 tumors that were pAkt 
negative/IL-6 negative, 79% (34/43) were also negative 
for pSTAT3 whereas 40% (6/15) of pAkt positive/
IL-6 positive tumors were also positive for pSTAT3, 
indicating that the loop Akt/IL-6 may represent one of the 
mechanisms that lead to activation of STAT3 in NSCLC.
DISCUSSION
NSCLC originates from a population of cells 
endowed with tumor-initiating potential denoted 
TICs [2, 3]. TICs isolated from NSCLCs are defined 
functionally for their ability to grow as spheres in vitro 
and for their tumorigenic potential in vivo [5, 6, 8, 9]. 
In this manuscript we report that aberrant activation of 
PI3K/Akt pathway plays a critical role in the proliferation, 
self-renewal and tumorigenicity of NSCLC TICs by 
establishing an autocrine IL-6/IL-6r signalling loop that 
activates STAT3 (Figure 8B). The data obtained in the 
in vitro experiments with cultured NSCLC cells were 
confirmed by the correlative studies in NSCLC tissues.
The first relevant observation of this manuscript is 
that aberrant activation of Akt - achieved through gain-
of-function mutations of Akt1, PIK3CA or by loss of 
PTEN - results in an increase of number and self-renewal 
capability of TICs in immortalised human bronchial 
epithelial cells and consequent acquisition of a high 
tumorigenic potential. These findings indicate that the 
molecular alterations that activate Akt signalling are able 
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Figure 7: LCS formation and tumorigenicity of NSCLC cells are regulated through STAT3 activity. A. Immunoblot 
analysis of phosphorilated and total STAT3 (pY705) in PEd/10-scr, PEd/10-shAkt1 and PEd/10-shIL-6r cells. B. Immunoblot analysis 
of phosphorylated (pY705) and total STAT3 in PEd/10-scr cells grown as LCS or in adherent conditions. C. Number of primary LCSs 
generated from PEd/10 cells or the corresponding cells interfered for STAT3 (PEd/10-shSTAT3; clones #1, #2). ***p < 0.001, *p < 0.05. 
D. Analysis of size distribution (μm) of LCSs generated from PEd/10 cells and derivatives by phase-contrast microscopy ***p < 0.001. 
E. Analysis of spheroid forming capability of NCI-H460 cells and PEd/10 cells in the presence of Sta-21 and Stat3 Inhibitor XIII at 
the indicated concentrations (upper and lower panels, respectively). ***p < 0.001, *p < 0.05. F. Tumor growth of PEd/10-scr and the 
corresponding cells interfered for STAT3 injected into immunodeficient mice (n = 5/group). G. STAT3 occupancy (fold enrichment) of 
JunB promoter as determined by Chip of cross-linked DNA extracted from control PEd/10-scr, PEd/10-shAkt1 and PEd/10-shSTAT3 
cells growing in complete (C), serum free (−) and serum free plus IL-6 (+) medium using anti-STAT3 or control IgG isotype antibodies. 
H. Relative mRNA expression of STAT3 target genes in PEd/10-scr and PEd/10-shAkt1 cells by Q-RT-PCR analysis.
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to increase TIC compartment in NSCLC and are consistent 
with previous studies that have revealed preferential 
activation of the PI3K/Akt pathway in cells inside spheres 
and a role for PI3K signalling in survival and proliferation 
of cancer stem-like cells [11, 12]. Accordingly, nuclear 
localized Akt as been shown to enhance breast cancer 
stem-like cells through inactivation of cell cycle inhibitors 
p21 and p27 or through FoxO-Bim pathway [44, 45].
The results of self-renewal experiments indicate 
that active Akt signalling may shift the balance between 
Figure 8: Akt activation correlates with activated STAT3 and IL-6 level in primary NSCLC. A. Representative images of 
immunohistochemical analysis of TMAs of human primary lung cancer for pAkt (S473), IL-6 and pSTAT3 (Y705). Magnification 40X. 
B. The cartoon shows the Akt1/NF-kB/IL-6/STAT3 signalling pathway operating in NSCLC TICs.
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asymmetric to symmetric division, as recently suggested 
to occur in breast cancer cells [46]. On the other 
hand, the critical role of Akt1 in TICs was confirmed 
by shRNA experiments in established and primary 
NSCLC cells, in which Akt1 inhibition suppressed 
LCS formation, self-renewal capacity, expression of 
stemness-related markers and in vivo tumorigenic 
potential. However, it is to be noted that the experiments 
with Akt2 shRNAs or pharmacological inhibitors, 
indicate that aberrant signalling through the PI3K/
Akt pathway in NSCLC TICs is funnelled through the 
diverse Akt isoforms, and thus that efficient suppression 
of all isoforms is required for the eventual eradication 
of NSCLC TICs.
A second notable finding of our work is the 
identification of critical targets of constitutive Akt1 
signalling that contribute to maintain cancer stem-like 
properties of NSCLC TICs. Accordingly, IL-6 turned out 
to be a critical effector of activated Akt1 in NSCLC TICs. 
In fact, although the most prominent role of IL-6 is to 
regulate immune and inflammatory responses [47], IL-6 
has also been implicated in the regulation of growth, drug 
resistance and metastatic spread of tumors [48, 49]. The 
findings reported here extend previous observations that 
IL-6 is overexpressed in lung cancer [50, 51] and point to 
activation of PI3K/Akt pathway as one of the causes of 
the observed IL-6 overproduction. In fact we report that 
Akt1 suppression by shRNA in NSCLC cells decreases 
IL-6 levels whereas active Akt1, active PIK3CA and/or 
loss of PTEN increase IL-6 levels.
Moreover, the finding that IL-6 was, among the 
genes down-regulated in NCI-H460 cells interfered 
for Akt1, the DEG that resulted most consistently up-
regulated in NSCLC LCSs, suggested that it plays a 
role in mediating the effects exerted by Akt1 on NSCLC 
TICs. Indeed experiments in this manuscript indicated 
that the production of IL-6 induced by activated Akt1 
is able to promote self-renewal and tumorigenicity of 
NSCLC TICs. In fact, exposure of LCSs from BEAS-
Akt1-E17K or from NSCLC cells to blocking anti-IL-6 
mAbs markedly reduced the capability of these cells 
to generate LCSs; conversely, administration of IL-6 
to BEAS-2B cells or to NSCLC cells interfered for 
Akt1, restored the capability to generate LCSs. These 
results are in agreement with previous studies showing 
that IL-6 promotes the recruitment of tumor cells into 
the metastatic niche [52], regulates self-renewal of 
breast cancer TICs in mammospheres and mediates 
Table 1: Correlation among phosphorylated Akt1, phosphorylated STAT3 and expression of IL6 
in NSCLC patients
pAkt negative pAkt positivea
IL-6/pSTAT3 negative 34 9
IL-6/pSTAT3 positiveb,c 10 7
Total 44 16
aAkt activation was evaluated with phospho-specific antibodies (pS473) and scored as negative (<10% of the tumour 
cells with weak, focal immunopositivity or absence of staining) and positive (>10% of tumour cells with strong or diffuse 
immunopositivity).
bIL-6 was evaluated with specific antibodies and scored as negative (<10% of the tumour cells with weak or absence of 
staining) and positive (>10% of tumour cells with strong or diffuse immunopositivity).
cSTAT3 activation was evaluated with phospho-specific antibodies (Y705) and scored as negative (<5% of the tumour cells 
with weak or absence of staining) and positive (>5% of tumour cells with strong or diffuse immunopositivity).
n = 94; p = 0.044
Table 2: Correlation of phosphorylated Akt1 with IL-6 expression and phosphorylated STAT3 in 
NSCLC patients
pSTAT3 negative pSTAT3 positivec Total
Akt negative/IL-6 negative 34 9 43
Akt positive/IL-6 positivea, b 9 6 15
Total 43 15 58
aSee Table 1. 
bSee Table 1.
cSee Table 1. n = 94; p = 0.029
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the conversion of differentiated cancer cells in cancer 
stem-like cells [53–55].
The observation that LCS formation, self-renewal 
capacity and tumorigenic potential of NSCLC cells were 
markedly impaired by inhibition of IL-6 receptor, pointed 
to an epithelial cell-specific action of IL-6. This finding is 
of particular interest in the light of the fact that genes that 
are frequently mutated in NSCLC (i.e. EGFR, KRAS) 
rely on PI3K/Akt to convey their oncogenic effects 
[56, 57], and suggest that IL-6/IL-6r may be a general 
downstream effector of several oncogenes in NSCLC 
TICs. Accordingly, recent work indicated that mutant 
EGFR induces resistance to irreversible EGFR inhibitors 
in NSCLC through the activation of IL-6 receptor/
JAK1/STAT3 signaling [58]. The results described here 
in human, complement also data from murine models 
of lung cancer, which have shown that IL-6/STAT3 
signaling facilitates cancer progression by promoting cell 
growth [59, 60].
As to the mechanism, our data indicate that Akt 
regulates IL-6 production in NSCLC cells by inducing 
IkB degradation, which allows NF-kB to enter the nucleus 
and activate IL-6 transcription [61, 62] and, on the other 
hand, that a critical effector of IL-6 is STAT3. In fact, 
interference with Akt1- or IL-6-dependent signalling in 
NSCLC cells impairs STAT3 phosphorylation (Y705) 
and activity whereas active Akt1 up-regulated them. 
Second, interference with Akt1-dependent signalling 
impairs occupancy of STAT3 targets’ promoters and 
modulates their mRNA expression. Third, STAT3 is 
strongly hyperactivated in NSCLC LCSs compared with 
cells grown in adherence. Fourth, interference with STAT3 
impairs baseline and IL-6-dependent LCS formation, 
self-renewal capacity and tumorigenic potential. Finally, 
STAT3 is constitutively activated in 30–40% of NSCLC, 
with a positive correlation with pAkt/IL-6 positivity. These 
findings extend previous work demonstrating STAT3 
activation in a number of cancers of epithelial origin [63] 
including NSCLC [64] and may provide a molecular 
mechanism to explain how constitutively activated 
STAT3 contributes to the development of lung cancer [65]. 
Accordingly, an IL-6/STAT3 pathway was preferentially 
active in CD44+/CD24- breast cancer stem cells [66] and 
PTEN was shown to negatively regulate TIC manteinance 
through STAT3-dependent signalling [67]. It is of note that 
STAT3 inhibition abrogate IL-6-dependent conversion of 
ALDH (low) prostate cancer cells to ALDH(high) [55] 
whereas STAT3 activation induces a melanoma-initiating 
cell phenotype that could favor chemotherapy resistance 
and relapse [68].
Moreover, one of the STAT3 targets analysed in 
this work, Cyclin D2, has recently been reported to be 
expressed in glioblastoma TICs and to regulate their 
growth in vivo [69].
Finally the TMA data suggest that activation of 
the PI3K/Akt/IL-6 axis may represent one mechanism 
that lead to activation of STAT3 in NSCLC, though not 
sufficient to account for all cases. Accordingly, recent 
proteomic results have demostrated that PI3K-dependent 
STAT3 activation may be also mediated by other 
molecules such as the tyrosine kinase expressed in 
hepatocellular carcinoma kinases (TEC) [70]. Such 
alternative mechanisms of STAT3 activation may 
account for the STAT3-positive tumors that are negative 
for Akt.
In conclusion the results presented here suggest that, 
among the multiple pathways that are activated in NSCLC, 
aberrant PI3K/Akt signalling contributes to promote and/
or maintain NSCLC TICs by eliciting an autocrine IL-6/
IL-6r loop that activates the transcription factor STAT3. 
These data provide novel potential therapeutic targets, in 
agreement with recent work showing that novel theanine 
derivatives may have therapeutic applications in the 
treatment of lung cancers by targeting EGFR/VEGFR-
Akt/NF-κB pathways [71].
MATERIALS AND METHODS
Cell culture
BEAS-2B cells were purchased from LGC 
Standards (Milan, IT) and cultured in bronchial epithelial 
cell growth medium (BEBM) supplemented with growth 
factors (BEGM) (Cambrex Bio-science, Walkersville, 
MD). NCI-H460 cells were purchased from ATCC-LGC 
Promochem (London, UK). Primary lung cancer cells 
PEd/10 were derived from malignant pleural effusions of 
adenocarcinoma patients [24]. NCI-H460, PEd/10 cells 
were cultured in RPMI-1640 (Invitrogen, Carlsbad, 
CA), supplemented with 10% of fetal bovine serum and 
100 units/ml penicillin-streptomycin (Life Technologies, 
London, UK).
shRNA and viral infection
The shRNA for human Akt1 (NM_005163), 
Akt2 (NM_001626) IL-6r (NM_000565), STAT3 
(NM_003150) and the Mission non-target control 
transduction virus (Sigma SHC002V) were from the 
Mission Program shRNA (Sigma-Aldrich, St. Louis, 
MO). pLenti-DEST-6.2-Akt1-E17K vector was obtained 
by Gateway Technology (Invitrogen). Lentiviral particles 
were packaged in HEK293T cells. Cells were transduced 
by spin infection selected with 1 μg/ml puromycin and 
5 μg/ml blasticydin (Invitrogen).
Enrichment of LCSs
LCSs were obtained by plating 10,000 cells/ml 
in serum-free DMEM-F12 medium (Gibco-Invitrogen) 
containing 10 μg/ml insulin (Sigma-Aldrich, St. Luis, 
MO), 1% Albumin Bovine Fraction V (Sigma-Aldrich) 50 
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ng/ml EGF and 25 ng/ml bFGF (PeproTech, London, UK) 
(sphere medium) in ultra-low attachment flasks. LCSs 
were expanded by trypsinization and mechanical 
dissociation followed by re-plating of single cell 
suspensions (10,000 cells /ml) in fresh sphere medium. 
Self-renewal of LCSs was tested by assessing the capacity 
of primary LCSs to generate secondary LCSs after trypsin 
disaggregation. Secondary LCSs were assessed at day 
7 for NCI-H460 and BEAS-2B cells and at day 12 for 
PEd/10 cells.
Anti-IL-6 mAb and recombinant human IL-6 were 
purchased from PeproTech. Cells were treated with 
LY294002 (Sigma-Aldrich), MK2206 (Selleckchem, 
Huston, TX), BAY11-7082 (Sigma-Aldrich), STA-21 
(Enzo Life Science, Firenze, Italy) and STAT3 Inhibitor 
XIII (Calbiochem, Darmastadt, Germany). Drugs were 
added to cells every 4 days. The number of LCSs 
was assessed by counts under the microscope. LCSs 
diameters were determined using ImageJ software (NIH, 
Bethesda, MD).
Experiments were repeated at least three times 
and data are shown as mean ± SD of three independent 
experiments.
Quantitative reverse transcription real-time 
PCR (Q-RT-PCR)
Total RNA was prepared as described [25]. 
Q-RT-PCR was performed using Power SYBR Green 
PCR Master Mix in an ABI Prism 7300 thermocycler 
(Applied Biosystems, Foster City, CA). Primers 
used in Q-RT-PCR are available upon request. Gene 
expression was normalised to GAPDH mRNA content. 
The relative amounts of mRNA were calculated by 
the comparative cycle threshold (CT) method [26]. At 
least three independent experiments were performed in 
triplicate and data are shown as mean ± SD.
ELISA
Levels of secreted IL-6 were assessed by ELISA 
in culture supernatants (Human IL-6 Quantikine ELISA 
Kit, R&D Systems, Minneapolis, MN), according 
to manufacturer’s instructions. The amount of IL-6 
concentration was normalized for cell number after 
48 h from plating. Three independent experiments were 
performed in triplicate and data are shown as mean ± SD.
Antibodies and western blot
Antibodies used for Western Blot were from: i) Cell 
Signaling Technology (Denver, MA), anti-phospho-Akt 
(S473) (#4058), anti-Akt1 (#2938), anti-Akt2 (#2964), 
anti-phospho-GSK3-αβ (Ser21/9) (#9331), anti-GSK3 
(#9338), anti-STAT3 (#9139), anti-phospho-STAT3 
(Y705) (#9145), anti-phospho-IkKα/β (Ser176/180) 
(#2697), anti-IkB (#9242), anti-phospho-IkB (Ser32) 
(#2859), anti-PTEN (#9552), anti-p110α (#4255); 
ii) Santa Cruz Biotechnology (Santa Cruz, CA), anti-IkKα 
(sc-7218); iii) Sigma-Aldrich, anti-β-actin (clone AC-74, 
#A2228).
Antibodies used for immunostaining were selected 
according to previously published work: anti-CK7 
(#35057) (Menarini, Florence, Italy), anti-CK34 (Enzo 
Diagnostics, Inc, Farmigale, NY), anti-pAkt Ser473 
(#3787) (Cell Signaling Technology), anti-pSTAT3 
Tyr705 (#9145) (Cell Signaling Technology), anti-IL-6 
(AF-206-NA) (R&D Systems, Minneapolis, MN).
Protein preparation and Western blot analysis were 
carried out by standard methods [27]. Densitometric 
analysis of gel bands was carried out with ImageJ software 
(NIH).
Luciferase assays
Cells were transfected with 1 μg of the NF-kB 
promoter/luciferase reporter plasmids plus 100 ng 
pRL Renilla as control vector (Promega, Madison, WI) 
with Fugene transfection reagent (Roche Molecular 
Biochemicals, Mannheim, Germany). Luciferase activity 
was rmeasured by Dual-Luciferase Reporter Assay 
System (Promega) using Thermo Scientific Varioskan 
Flash (Thermo, Waltham, MA). Basal luciferase activity 
was examined in cells transfected with an empty vector 
(pGL3 Basic Vector). Three independent transfections 
were performed for each construct in triplicate and data 
are shown as mean ± SD.
RNA profiling analysis
RNA concentration was determined with 
Nanodrop spectrophotometer (Nano-Drop, Wilmington, 
Germany) and its quality was assessed with Agilent 
2100 Bioanalyzer (Agilent Technologies, Santa Clara, 
CA). For each sample, 500 ng of total RNA were used 
to synthesize biotinylated cRNA with Illumina RNA 
Amplification Kit (Ambion, Austin, TX). Synthesis was 
carried out according to the manufacturers’ instructions. 
cRNA concentration and the quality were assessed out as 
described above. From each sample, technical replicates 
were produced and 750 ng cRNA were hybridized for 
18 h to Human HT-12_V3_0_R1 Expression BeadChips 
(Illumina, San Diego, CA) as described earlier [28]. 
Hybridized chips were washed and stained with 
streptavidin-conjugated Cy3 (GE Healthcare, Milan, 
Italy). BeadChips were dried and scanned with an 
Illumina Bead Array Reader (Illumina).
Data analysis
Expression gene lists were analysed by Gene-
Spring10.1 (Agilent Technologies) and DEGs were 
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selected on the basis of fold-change and statistical 
significance. Lists were filtered using fold-change ≥1.5 and 
p-value ≤ 0.01 as thresholds in T-test. DEGs were used to 
evaluate the functional behaviour in terms of Biological 
Processes and Molecular Function, Development 
Function, Disease and Disorder. The degree of enrichment 
was evaluated to determine whether an observed level 
of annotation for a group of genes was statistically 
significant. In particular, for each term, a q-value was 
computed by the Hypergeometric test (p ≤ 0.05) and 
corrected using False Discovery Rate (FDR) [29]. The 
terms with a q-value exceeding the significance threshold 
were then selected as representative. Pathway analysis 
was performed using Ingenuity Pathway Analysis (IPA, 
Ingenuity Systems).
Tumorigenicity assays
Tumorigenicity assay were performed as follows: 
NCI-H460 (1 × 106), PEd/10 (3 × 106), BEAS-2B 
(5 × 106) cells and the corresponding derivatives were 
subcutaneously injected into the right flank of 6-week-old 
athymic nude mice (Charles River, Erkrath, Germany). 
Control BEAS-2B and derivatives grown as LCSs 
(4 × 103 or 4 × 104) were injected subcutaneously into 
NOD/Scid mice (Charles River). Tumor growth was 
monitored every 7 days and measured with an external 
caliper. Tumor volume was calculated as follows: tumor 
volume (mm3) = ½ (length × width2) [30].
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) was 
carried out with Imunoprecipitation Assay Kit (Upstate 
Biotechnology) according to the manufacturer’s 
instruction. Approximately 107 cells were fixed in 1% 
formaldehyde and 125 mM glycine. Cells were lysed and 
chromatin sonication was performed with a Bioruptor 
Diagenode model UCD300 to obtain an average fragment 
length of ~400 bp. Samples were precleared with protein 
A-G Sepharose and incubated overnight at 4°C with 
2 μg of antibody anti-IgG or anti-STAT3, sc-482 (Santa 
Cruz Biotechnology). Input and immunoprecipitated 
DNAs were analyzed by PCR performed with 
AmpliTaq Gold DNA polymerase (Perkin-Elmer, MA, 
USA), resolved on 2% agarose gel and scanned using 
GelDoc (BioRad, Hercules, CA). Primers used were 
5′-GCCGCTGTTTACAAGGACAC-3′ (forward) and 
5′-CTAGTCAGCCACGGAAGTGC-3′ (reverse).
Patients
Patient accrual was conducted according to internal 
Review Board of the INT Fondazione Pascale (Naples, 
Italy) (CEI 556/10 of 12/3/2010) and the study was 
approved by the internal Review Board of the AOU 
Mater Domini/University Magna Graecia (Catanzaro, 
Italy) in the meeting of 16/3/2011. All animal work was 
conducted according to the relevant Italian guidelines 
and was approved by the Internal Committee for Animal 
Study (CESA) of the Institute for Genetic Research on 
April 7th 2008 (CESA 10-08). Archive material from 
104 patients diagnosed of NSCLC was collected from 
INT Fondazione Pascale (Naples, Italy) and University of 
Catanzaro. Median age was 64 year old (range 28–82). 
Among patients with clinical data available, women were 
32 and males 72. Stage was known for 92 patients: 79 
patients had stage I–II disease and 13 had stage III–IV 
disease. Grade was known for 75 patients: 52 cases were 
G1–G2 and 23 were G3–G4.
TMA generation and immunohistochemistry
TMAs were constructed using Galileo TMA 
CK3500 Tissue Microarrayer (ISE TMA Software, 
Integrated System Engineering). Immunostaining was 
performed using the avidin-biotin-peroxidase method 
(Novocastra, Newcastle, UK) on formalin-fixed, paraffin-
embedded tissues as described [19, 27, 31]. Positive 
immunohistochemical scores were selected on the basis 
of established criteria: pAkt and IL-6 was scored positive 
when >10% of tumor cells were positive, respectively 
[32, 33]; pSTAT3 was scored positive when >5% of tumor 
cells were positive [34].
For each one immunohistochemical round a negative 
control has been included by replacing the primary 
antibody with solvent. All controls gave satisfactory 
results. Stained TMA sections were evaluated by an expert 
pathologist (R.F.).
Statistical analysis
Data presented are the means ± SD of at least 3 
independent assays (number and diameter of spheres, 
ELISA assay, Luciferase assay, Q-RT-PCR). Number 
and diameter of spheres, fold increase were analyzed 
by Student’s t-test and ANOVA using the statistical 
software GraphPad Prism 4. Fischer’s exact test was 
used to assess the correlation between pAkt, pSTAT3 and 
IL-6 expression. Data analysis and summarization were 
conducted using SPSS 20 (SPSS Inc., Chicago, IL, USA). 
Significance was set with p value of at least at p ≤ 0.05. In 
the figures the number of asterisks corresponds to p ≤ 0.05 
(*), p ≤ 0.01 (**), p ≤ 0.001 (***) and p ≤ 0.0001 (****), 
respectively.
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